A clinical study of alpha-Galactosylceramide pulsed dendritic cells (Chiba-NKT) in patients with advanced or recurrent non-small cell lung cancer. A phase II study.

Phase 2

• Conditions: unresectable or recurrent non-small cell lung cancer

• Registration Number: JPRN-UMIN000007321
• Lead Sponsor: Department of General Thoracic Surgery, Graduate school of Medicine, Chiba University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-17
• Study Completion: 2017-08-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

Patients matching any of the following criteria. Patients who have serious complications such as severe infection or malnutrition. Patients with pleural effusion or ascites, pericardial effusion, uncontrolled brain metastasis, simultaneous double cancer, receiving corticosteroid treatment, autoimmune disease, a past history of hepatitis, positive for HBs antigen, anti-HCV antibody, anti-HIV antibody, anti-HTLV-1 antibody, severe cardiac disease(NYHA classIII or more) or respiratory disease(Hugh-Jones classIII or more). Patients with a past history of hypersensitivity to albumin. Pregnant or breast feeding women. Patients whose medical condition cannot allow leukoapheresis. Patients who are considered ineligible to participate in the clinical trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified